Avoro Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $984M | Buy |
1,833,333
+15,152
| +0.8% | +$7.76M | 8.84% | 4 |
|
|
2026
Q1 | $952M | Buy |
1,818,181
+10,681
| +0.6% | +$5.1M | 9.36% | 3 |
|
|
2025
Q4 | $1.05B | Sell |
1,807,500
-25,500
| -1% | -$13M | 10.35% | 3 |
|
|
2025
Q3 | $841M | Sell |
1,833,000
-42,000
| -2% | -$15.7M | 10.87% | 3 |
|
|
2025
Q2 | $567M | Sell |
1,875,000
-147,222
| -7% | -$43.9M | 9.94% | 4 |
|
|
2025
Q1 | $670M | Sell |
2,022,222
-6,778
| -0.3% | -$2.23M | 10.46% | 4 |
|
|
2024
Q4 | $626M | Hold |
2,029,000
| – | – | 8.86% | 4 |
|
|
2024
Q3 | $431M | Sell |
2,029,000
-26,555
| -1% | -$6.79M | 6.28% | 5 |
|
|
2024
Q2 | $576M | Buy |
2,055,555
+111,111
| +6% | +$26.4M | 7.67% | 2 |
|
|
2024
Q1 | $519M | Buy |
1,944,444
+55,556
| +3% | +$13.1M | 6.06% | 5 |
|
|
2023
Q4 | $437M | Buy |
1,888,888
+333,888
| +21% | +$58.4M | 6.04% | 5 |
|
|
2023
Q3 | $227M | Buy |
1,555,000
+39,849
| +3% | +$7.5M | 3.54% | 12 |
|
|
2023
Q2 | $350M | Sell |
1,515,151
-151,515
| -9% | -$41M | 4.75% | 6 |
|
|
2023
Q1 | $404M | Buy |
1,666,666
+6,666
| +0.4% | +$1.82M | 5.99% | 6 |
|
|
2022
Q4 | $482M | Buy |
1,660,000
+125,000
| +8% | +$12.2M | 7.2% | 4 |
|
|
2022
Q3 | $99.8M | Hold |
1,535,000
| – | – | 1.84% | 15 |
|
|
2022
Q2 | $110M | Buy |
1,535,000
+110,000
| +8% | +$8.09M | 2.17% | 13 |
|
|
2022
Q1 | $140M | Hold |
1,425,000
| – | – | 2.55% | 15 |
|
|
2021
Q4 | $121M | Hold |
1,425,000
| – | – | 2.06% | 14 |
|
|
2021
Q3 | $114M | Hold |
1,425,000
| – | – | 1.79% | 16 |
|
|
2021
Q2 | $139M | Hold |
1,425,000
| – | – | 2.41% | 12 |
|
|
2021
Q1 | $167M | Buy |
1,425,000
+200,000
| +16% | +$23.3M | 2.88% | 10 |
|
|
2020
Q4 | $136M | Buy |
1,225,000
+335,000
| +38% | +$40.9M | 2.35% | 13 |
|
|
2020
Q3 | $106M | Buy |
890,000
+540,000
| +154% | +$58.6M | 1.5% | 14 |
|
|
2020
Q2 | $39.6M | Buy |
350,000
+1,000
| +0.3% | +$98.3K | 0.78% | 25 |
|
|
2020
Q1 | $23.3M | Hold |
349,000
| – | – | 0.79% | 27 |
|
|
2019
Q4 | $31.8M | Sell |
349,000
-11,000
| -3% | -$1.07M | 0.93% | 19 |
|
|
2019
Q3 | $31M | Hold |
360,000
| – | – | 1.29% | 20 |
|
|
2019
Q2 | $37.7M | Buy |
360,000
+50,000
| +16% | +$5.36M | 1.3% | 18 |
|
|
2019
Q1 | $38.8M | Buy |
310,000
+85,000
| +38% | +$10.6M | 1.68% | 18 |
|
|
2018
Q4 | $25.4M | Sell |
225,000
-238,000
| -51% | -$36.8M | 1.52% | 15 |
|
|
2018
Q3 | $99.1M | Sell |
463,000
-26,536
| -5% | -$6.66M | 4.55% | 7 |
|
|
2018
Q2 | $137M | Buy |
+489,536
| New | +$86M | 5.27% | 6 |
|
Other funds holding MDGL
BBA
RI
JT
PC
Avoro Capital Advisors's MDGL Position: Q2 2026 in Review
Avoro Capital Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 0.83% in Q2 2026, buying an estimated $7.76M and bringing the position to 1,833,333 shares worth $984M. The position accounts for 8.84% of the portfolio, ranked #4.
Avoro Capital Advisors first reported a position in MDGL in Q2 2018 and has held it in 33 quarters since. The position peaked at $1.05B in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- Avoro Capital Advisors held 1,833,333 shares of Madrigal Pharmaceuticals worth $984M as of Q2 2026.
- Avoro Capital Advisors bought 15,152 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.76M.
- Madrigal Pharmaceuticals made up 8.84% of Avoro Capital Advisors's portfolio in Q2 2026, its #4 holding.
- Avoro Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Avoro Capital Advisors's Madrigal Pharmaceuticals position peaked at $1.05B in Q4 2025.
- 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.